CD274 and neoplasm: RT can not only increase the expression of programmed death ligand 1 (PD-L1) on tumor cells but also inhibit T-cell activation along the PD-1/PD-L1 axis, so that specific anti-PD-1 antibodies can then interact at this point [20,21,22].